NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
4 trialsNCT06866574 2025-07-31
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Phase 3 Active not recruiting
NCT06465914 2024-12-12
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
Shanghai Bovax Biotechnology Co., Ltd.
Phase 3 Active not recruiting
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting